Patients who were previously facing challenges like needing oxygen after just a few steps or struggling with breathlessness from simple movements are finding new possibilities for daily life.
Preterm infants have poorly formed lungs, and struggle to breathe. Maryland startup Therabron Therapeutics just raised $6.75 million for its Phase 2 drug that helps regulate breathing in infants with respiratory difficulties.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.